Use this Dicloxacillin pediatric dose calculator to match the prescribed child dose to the exact liquid, tablet, or capsule strength before you give it.
dose calculator basics
Use this Dicloxacillin calculator as the fast parent page for weight-based dose checks, mL conversion, common strengths, and the practical safety steps that generic calculator sites often skip.
mL per dose = (child weight in kg x prescribed mg/kg/day / doses per day) / medication concentration in mg per mL.
For a 20 kg child using 25 mg/kg/day divided 4 times daily with 62.5 mg/5 mL, calculate the daily mg target, divide by the schedule, then convert that mg amount into mL for the selected product.
Practical dosing guide
Use this page to match the prescribed Dicloxacillin plan to the exact product strength and schedule before the first dose.
Dicloxacillin is a penicillinase‑resistant penicillin used for infections due to methicillin‑susceptible Staphylococcus aureus (MSSA).
Administer on an empty stomach every 6 hours; food reduces peak concentrations and compromises time-above-MIC goals for MSSA.
Rotate to dicloxacillin only after susceptibility data exclude MRSA, as the agent lacks activity against resistant staphylococci, enterococci, and anaerobes.
Dicloxacillin is a narrow oral antistaphylococcal penicillin used when MSSA coverage is needed and reliable q6h empty-stomach dosing is feasible.
Bullous/non-bullous impetigo and ecthyma due to MSSA: Use when MSSA is confirmed or strongly suspected; switch if MRSA suspected.
Nonpurulent cellulitis or post-I&D MSSA abscess: Switch to cephalexin if adherence barriers to q6h dosing emerge.
MSSA surgical site infections after IV therapy: Start after afebrile >=24 hours with confirmed MSSA susceptibility.
MSSA osteomyelitis or septic arthritis (oral completion phase): Use after 7-10 days IV therapy with clinical improvement.
MSSA bacteremia step-down after clearance: Specialist-directed step-down only; not a routine default for pediatric S. aureus bacteremia.
Chronic suppressive therapy for MSSA hardware infections when removal is not feasible: Reserve for cases where hardware removal is not feasible; reassess for removal when possible.
Most children tolerate dicloxacillin, but nausea, loose stools, and rash are still common reasons families call back. Watch hydration and daily function closely. Contact your pediatric clinician for persistent vomiting or diarrhea, poor intake, or new jaundice. Seek urgent care for breathing trouble, facial swelling, blistering rash, severe abdominal pain, or blood in stool.
Dicloxacillin is an isoxazolyl penicillin that resists many staphylococcal beta-lactamases. It binds penicillin-binding proteins and inhibits peptidoglycan cross-linking, leading to bacterial cell-wall failure and lysis in susceptible organisms. Its clinical activity is strongest against MSSA and selected streptococci, not MRSA. Because beta-lactam killing is time-dependent, missed doses and food-related absorption reductions can meaningfully lower effectiveness.
Food significantly lowers absorption. Taking doses 1 hour before or 2 hours after meals keeps blood levels high enough to kill MSSA bacteria.
Take it as soon as you remember if it’s within about 2 hours. Otherwise skip it and go back to the regular schedule—never double up doses.
Most skin infections improve within 48–72 hours. Call your clinician if redness spreads, fever persists, or drainage increases despite treatment.
Mild stomach upset is common. Give the next dose with a small sip of water or bland snack while still keeping the empty-stomach spacing. Call if vomiting persists, the child shows signs of dehydration, or stools become bloody—these require clinician review.
It can reduce the effectiveness of some hormonal contraceptives and may increase the effect of warfarin. Always share a full medication list, including supplements, so the clinician can adjust contraception plans or monitor blood thinners.
Seek help immediately for hives, swelling, trouble breathing, severe diarrhea, jaundice, or if the infection worsens rapidly with spreading redness, high fever, or new joint pain.
idsa-ssti-2014
cdc-impetigo-2024
aafp-cellulitis-2015
cid-osteomyelitis-2017
cid-bacteremia-2019
Clinical Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections
Infectious Diseases Society of America
Source